Formoterol and ciclesonide combination

Details for Australian Patent Application No. 2004246819 (hide)

Owner ALTANA Pharma AG

Inventors Mueller, Helgert; Dietzel, Klaus

Agent Griffith Hack

Pub. Number AU-A-2004246819

PCT Pub. Number WO2004/110460

Priority 03013510.7 13.06.03 EP

Filing date 9 June 2004

Wipo publication date 23 December 2004

International Classifications

A61K 31/58 (2006.01) - containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin

A61K 9/12 (2006.01) Medicinal preparations characterised by special physical form - Aerosols

A61K 31/167 (2006.01) - having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2004/110460 Priority application(s): WO2004/110460

22 November 2007 Change of Name(s) of Applicant(s), Section 104

  ALTANA Pharma AG The name of the applicant has been changed to Nycomed GmbH

13 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004246820-Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight

2004246817-Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioidbased treatments